Iovance Biotherapeutics announced layoffs of less than 20% of its workforce following a slow commercial launch of Amtagvi, a tumor-infiltrating lymphocyte (TIL) cell therapy approved earlier in 2024 for melanoma. Despite being the first marketed cellular therapy of its kind, Amtagvi faced challenges including complex manufacturing and high price points near $515,000 per treatment. Revised 2025 revenue forecasts were cut by 40%, reflecting tempered demand and impacting operational strategy. Iovance’s restructuring aims to extend cash runway while maintaining commitment to advancing cell therapy innovations.